Wedoany.com Report on Feb 9th, For individuals seeking PrEP (pre-exposure prophylaxis), an HIV test is first required. If the test result is negative, healthcare professionals need to assess their suitability for PrEP use. This includes evaluating risks such as adverse reactions to drug components, contraindications, symptoms of acute HIV infection, or potential cross-reacting medications (e.g., anti-tuberculosis drugs). Understanding a person's complete medical history is crucial for the effective use of PrEP and achieving desired outcomes.

Professor Omu Anzala, a virologist at the University of Nairobi, pointed out that Lenacapavir is an antiviral drug that directly targets the HIV virus, with a mechanism of action similar to other existing antiretroviral drugs. Professor Anzala stated, "It is purely antiviral. It is not a vaccine. It is a drug that directly targets the virus itself." As a member of the HIV vaccine and drug research team, Professor Anzala emphasized that this long-acting injection adds a new option to existing HIV prevention strategies, including condoms, vaginal rings, and daily oral tablets.

Clinical data show that this long-acting injection is up to 99% effective in preventing HIV transmission and may help address challenges related to medication adherence. The injection is administered subcutaneously in the abdominal area by a healthcare provider and is designed to be discreet and convenient. Trials found that, aside from mild to moderate injection site reactions, the incidence of adverse events showed almost no difference compared to other regimens. Compared to oral PrEP, the drug also showed no adverse effects on pregnancy and birth outcomes.

Promotion efforts will be coordinated by the Ministry of Health through the National AIDS and STI Control Programme (Nascop) in collaboration with partner organizations. This long-acting injection provides a more diverse range of administration options for HIV prevention, helping to meet the needs of different populations.